DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Yau T, Park JW, Finn RS. et al.
CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).
Ann Oncol 2019;
30: v874-v875
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.